US FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma

By
Emily Salmini
-
0
49
Wugen, Inc. announced that it has received Breakthrough Therapy Designation from the US FDA for its investigational CAR-T cell therapy, Sofi-cel.
[Wugen, Inc.]
Full Article